Adaptive Biotechnologies (ADPT) Asset Writedowns and Impairment (2025 - 2026)
Adaptive Biotechnologies' (ADPT) quarterly Asset Writedowns and Impairment came in at $347000.0 in Q1 2026, up 443.56% year-over-year from $63837.9 in Q1 2025, and down 38.37% quarter-over-quarter from $563000.0 in Q4 2025.
Powered by 
Analysis
Adaptive Biotechnologies (ADPT) Asset Writedowns and Impairment (2025 - 2026) Analysis & Trends
Adaptive Biotechnologies has disclosed Asset Writedowns and Impairment across 2 years of filings, most recently posting $347000.0 for Q1 2026.
- In Q1 2026, Asset Writedowns and Impairment rose 443.56% year-over-year to $347000.0; the TTM figure through Jun 2026 stood at $910000.0 (up 2078.26% YoY), while the FY2025 annual figure was $563000.0, down 92.19% from the prior year.
- Asset Writedowns and Impairment came in at $347000.0 for Q1 2026 at Adaptive Biotechnologies, down from $563000.0 in the prior quarter.
- In the past five years, Asset Writedowns and Impairment ranged from a high of $563000.0 in Q4 2025 to a low of -$101000.0 in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Natera | 49.39 Bn | 48.29 Bn | 486.15 Mn |
| 2 | Quest Diagnostics | 27.49 Bn | 26.86 Bn | 1.03 Bn |
| 3 | Labcorp Holdings | 26.51 Bn | 26.37 Bn | 1.11 Bn |
| 4 | Guardant Health | 23.17 Bn | 22.12 Bn | 219.03 Mn |
| 5 | Tempus AI | 12.59 Bn | 11.77 Bn | 274.25 Mn |
| 6 | Caris Life Sciences | 8.01 Bn | 7.22 Bn | 182.38 Mn |
| 7 | Sotera Health | 5.53 Bn | 5.17 Bn | 177.96 Mn |
| 8 | BillionToOne | 4.80 Bn | 4.25 Bn | 77.11 Mn |
| 9 | Adaptive Biotechnologies | 4.40 Bn | 4.05 Bn | 51.39 Mn |
| 10 | iRhythm Holdings | 3.68 Bn | 3.08 Bn | 163.21 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 347,000.00 |
| Dec 31, 2025 | 563,000.00 |
| Jun 30, 2025 | 55,000.00 |
| Mar 31, 2025 | -101,000.00 |